Crossmark

Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients

Crossref DOI link: https://doi.org/10.1007/s10549-022-06615-2

Published Online: 2022-05-14

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Papautsky, Elizabeth Lerner https://orcid.org/0000-0003-2771-9579
Carlson, Martha

Johnson, Sheila M.

Montague, Hannah

Attai, Deanna J.

Lustberg, Maryam B.
Funding

Funding for this research was provided by:

Pfizer/NCCN (G1740)
License Information

Text and Data Mining valid from 2022-05-14

Version of Record valid from 2022-05-14
More Information

Article History

Received: 11 February 2022

Accepted: 18 April 2022

First Online: 14 May 2022

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Illinois at Chicago’s Institutional Review Board (Protocol #2020-0859; Exemption Granted: 7/29/20).

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below